University Medical Center
Utrecht, 3584CX, Netherlands
Location status: Recruiting
Location contact
Erik J Aarnoutse, PhD
CONTACT
Mariska J Vansteensel, PhD
CONTACT
Nick F Ramsey, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06207591
The goal of this clinical trial is to demonstrate communication through a brain implant in people in locked-in state, i.e. people with severe paralysis and communication problems.
The main questions it aims to answer are efficient and stable control of Brain-Computer interface (BCI) functions for communication with attempted hand movements and operation of a keyword-based speech BCI.
Participants will be implanted with four electrode grids, with in total 128 electrodes, on the surface of the brain and a connector on the skull. Participation includes visits of researchers for recording and training at home, 2-3 times per week for one year. Extension of participation after one year is possible.
If successful, the participant will be able to use the BCI at home independently, without the presence of a researcher.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Not applicable
Utrecht, 3584CX, Netherlands
Location status: Recruiting
Erik J Aarnoutse, PhD
CONTACT
Mariska J Vansteensel, PhD
CONTACT
Nick F Ramsey, PhD
PRINCIPAL_INVESTIGATOR
Locked-In Syndrome (LIS) is a neurological condition in which communication is impossible, or profoundly impaired, due to loss of speech and other motor functions, while cognition is intact. The most distressing aspect of LIS is the inability to initiate and sustain communication. Existing assistive technologies (ATs) fall short of a remedy. An effective brain-computer interface (BCI) for communication would dramatically improve quality of life for people with LIS. Electrocorticography (ECoG) with non-penetrating subdural electrodes is a promising implantable approach for BCI. In this study, the "CortiCom system" (which stands for Cortical Communication) wil be used. This system combines an implantable assembly, consisting of four small high-density (HD) ECoG grids on the hand and speech areas of the motor cortex, totalling 128-channels, and a transcutaneous pedestal connector, with an external data acquisition system. With the CortiCom system the overall hypothesis will be tested that broader and more densely spaced ECoG electrodes can better tap into the spatial detail of the organization of the sensorimotor cortex in order to expand BCI function and restore meaningful communication in LIS. Specifically, the CortiCom system will substantially increase the number and density of electrodes recording from the brain to determine whether more sophisticated control and communication can be achieved with more comprehensive and detailed spatial sampling of representations for movements of the hand/arm and of speech articulators. Clinically meaningful outcomes for people with LIS include rapid reestablishment, and stable maintenance of communication, at minimum consisting of a caregiver call-button and menu selections.
Objective:
Primary Objective 1: Demonstrate efficient and stable control of essential BCI functions (initiate BCI, call caregiver, and menu selections). Primary Objective 2: Demonstrate efficient and stable operation of a keyword-based speech BCI.
Intervention:
Participants will be implanted with an assembly consisting of HD-ECoG electrode grids over the sensorimotor cortex and a transcutaneous pedestal connector. The assembly will be connected with an external data acquisition system during recordings. During recordings, feedback about the neural signals is given via a visual display and participants are trained to employ the neural signals for fast brain-based communication. Upon adequate performance, participants can independently (i.e., without researcher involvement) train with and use the system at home for validation of performance and usability. After implantation, participation has a duration of 1 year, with a possibility of extension.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Implant electrodes and pedestal connector and use, through amplifier and decoding, for control of BCI
Other names: CortiCom-Utrecht assembly
Time frame: 1 year
Accuracy: >80% sensitivity (true positive rate) for 1-command control, and 90% sensitivity and 80% classification accuracy (distinguishing between the six classes) for 6-command control
Time frame: 1 year
Speed characters or keywords per minute
Time frame: 1 year
Subjective Workload: Visual Analogue Scale Continuous scale: Little to no effort (0) - Much effort (5). Lower numbers are better.
Time frame: 1 year
Subjective Workload: National Aeronautics and Space Administration-Task Load Index Scale: 21 point Likert-type scale. Lower numbers are better.
Time frame: 1 year
User Satisfaction: Psychosocial impact of assistive devices scale. Likert-type scale -3, -2, -1, 0, 1, 2, 3. 3 is best result.
Time frame: 1 year
User Satisfaction: Quebec User Evaluation of Satisfaction with assistive Technology version 2.0.
Likert-type scale: Extremely dissatisfied - Dissatisfied - Slightly satisfied - Satisfied - Extremely satisfied. Extremely Satisfied is the best result.
Time frame: 1 year
Validation: Questionnaire to evaluate user satisfaction and ease of use of the home use software.
Likert-type scale: fully disagree - disagree - neither agree or disagree - agree - fully agree - not applicable. Fully agree is the best result.
Time frame: 1 year
the number of different commands that are successfully decoded, or the size of the decoded vocabulary
Time frame: 2 years
Longitudinal data of the 24-hour cycle after implantation of the impedance (in Ω). The data are fitted to determine trends and variance, over weeks, to determine improvement or deterioration of electrode-tissue interaction.
Time frame: 2 years
Longitudinal data of the 24-hour cycle after implantation of the raw power (after wavelet transform, in arbitrary units). The data are fitted to determine trends and variance, both within 24 hrs to detect a possible circadian pattern and over weeks, to determine improvement or deterioration of signal amplitude.
Time frame: 2 years
Longitudinal data of the 24-hour cycle after implantation of the task-related modulation in power (correlation in r2). The data are fitted to determine trends and variance, over weeks, to determine improvement or deterioration of modulation.
Time frame: 2 years
Longitudinal data of the 24-hour cycle after implantation of the BCI performance (task accuracy). The data are fitted to determine trends and variance, both within 24 hrs to detect a possible circadian pattern and over weeks, to see improvement or deterioration of accuracy.
Time frame: 2 years
Longitudinal data of independent use per day. The best result is 24h use. The data are fitted to determine trends and variance, both within 24 hrs to detect a possible circadian pattern and over weeks, to see increase or decrease of the hours of independent use.
Time frame: 2 years
qualitative description on device specifications and experimental parameters, such as the specific decoder settings, for future, larger scale, application of HD ECoG-BCIs.
Contact information is provided by the study sponsor or research team.
Erik J Aarnoutse, PhD
CONTACT
Mariska J Vansteensel, PhD
CONTACT
UMC Utrecht
Other
Investigation on the Cortical Communication (CortiCom) System
Acronym: CortiCom
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03567213
Amyotrophic Lateral Sclerosis, Brain Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT04468919
Amyotrophic Lateral Sclerosis, Autonomic Nervous System Diseases
Portland, Oregon, United States
View Trial DetailsNCT06094205
Amyotrophic Lateral Sclerosis, Anarthria
Sacramento, California, United States
View Trial DetailsNCT05470478
Amyotrophic Lateral Sclerosis, Brain Diseases
Providence, Rhode Island, United States
View Trial Details